Adam S. Grossman - 09 Feb 2026 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role: President and CEO, Director
Signature: /s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact
Issuer symbol: ADMA
Transactions as of: 09 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 11 Feb 2026, 21:00:19 UTC
Previous filing: 16 Dec 2025
Next filing: 17 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Grossman Adam S	President and CEO, Director	C/O ADMA BIOLOGICS, INC., 465 STATE ROUTE 17, RAMSEY	/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact	11 Feb 2026	0001542517

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADMA	Common Stock	Award	$0	+282,529	+14%	$0.000000	2,290,379	09 Feb 2026	Direct	F1, F2, F3, F4
holding	ADMA	Common Stock						1,143,426	09 Feb 2026	See Footnote	F5
holding	ADMA	Common Stock						580,957	09 Feb 2026	See Footnote	F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADMA	Stock Option (right to buy)	Award	$0	+444,711		$0.000000	444,711	09 Feb 2026	Common Stock	444,711	$16.37	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date.
F2	Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F3	(continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F4	(continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 975,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
F5	These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
F6	These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
F7	The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 9, 2030 in accordance with the Plan.